Reported organ toxicities among 1-year HCT survivors
Outcomes . | Alive at day +365 without PICU (N = 2157) . | Alive at day +365 with PICU (N = 214) . | P value . | ||
---|---|---|---|---|---|
N . | Prob (95% CI), % . | N . | Prob (95% CI), % . | ||
Congestive heart failure | 2116 | 206 | |||
1-y | 2106 | 0.5 (0.3-0.9) | 206 | 0.5 (0-1.9) | |
2-y | 1912 | 0.8 (0.5-1.2) | 171 | 1 (0.1-2.8) | .769 |
3-y | 1789 | 1 (0.6-1.5) | 155 | 1 (0.1-2.8) | |
5-y | 1435 | 1.2 (0.7-1.7) | 126 | 1 (0.1-2.8) | |
Renal failure requiring dialysis | 2113 | 206 | |||
1-y | 2081 | 1.6 (1.1-2.1) | 187 | 9.7 (6-14.1) | |
2-y | 1889 | 2.7 (2-3.4) | 153 | 13.6 (9.3-18.6) | <.001 |
3-y | 1768 | 2.9 (2.2-3.6) | 138 | 14.6 (10.1-19.8) | |
5-y | 1420 | 3.2 (2.5-4) | 111 | 14.6 (10.1-19.8) | |
Diabetes/hyperglycemia | 2026 | 200 | |||
1-y | 1923 | 5.1 (4.2-6.1) | 174 | 13.5 (9.1-18.6) | |
2-y | 1738 | 5.9 (4.9-6.9) | 142 | 14 (9.5-19.2) | .371 |
3-y | 1622 | 6 (5-7.1) | 127 | 14 (9.5-19.2) | |
5-y | 1309 | 6.5 (5.4-7.6) | 105 | 14 (9.5-19.2) | |
Noninfectious liver toxicity | 2112 | 205 | |||
1-y | 1718 | 18.7 (17.1-20.4) | 146 | 29.3 (23.2-35.7) | |
2-y | 1543 | 20.7 (19-22.4) | 118 | 30.7 (24.6-37.2) | .683 |
3-y | 1435 | 21.2 (19.5-23) | 107 | 31.3 (25.1-37.8) | |
5-y | 1102 | 22 (20.3-23.8) | 82 | 31.3 (25.1-37.8) | |
Stroke/seizure | 2116 | 205 | |||
1-y | 2051 | 3.1 (2.4-3.9) | 175 | 15.1 (10.5-20.4) | |
2-y | 1846 | 4.6 (3.7-5.5) | 146 | 17.1 (12.2-22.5) | .081 |
3-y | 1723 | 5.1 (4.2-6.1) | 132 | 18.6 (13.6-24.2) | |
5-y | 1336 | 5.5 (4.6-6.6) | 105 | 18.6 (13.6-24.2) | |
Noninfectious pulmonary dysfunction | 1987 | 175 | |||
1-y | 1845 | 7.2 (6.1-8.4) | 136 | 22.9 (16.9-29.4) | |
2-y | 1656 | 9.9 (8.6-11.2) | 109 | 27.5 (21.1-34.4) | .270 |
3-y | 1550 | 10.4 (9.1-11.7) | 102 | 27.5 (21.1-34.4) | |
5-y | 1252 | 10.7 (9.4-12.1) | 87 | 27.5 (21.1-34.4) |
Outcomes . | Alive at day +365 without PICU (N = 2157) . | Alive at day +365 with PICU (N = 214) . | P value . | ||
---|---|---|---|---|---|
N . | Prob (95% CI), % . | N . | Prob (95% CI), % . | ||
Congestive heart failure | 2116 | 206 | |||
1-y | 2106 | 0.5 (0.3-0.9) | 206 | 0.5 (0-1.9) | |
2-y | 1912 | 0.8 (0.5-1.2) | 171 | 1 (0.1-2.8) | .769 |
3-y | 1789 | 1 (0.6-1.5) | 155 | 1 (0.1-2.8) | |
5-y | 1435 | 1.2 (0.7-1.7) | 126 | 1 (0.1-2.8) | |
Renal failure requiring dialysis | 2113 | 206 | |||
1-y | 2081 | 1.6 (1.1-2.1) | 187 | 9.7 (6-14.1) | |
2-y | 1889 | 2.7 (2-3.4) | 153 | 13.6 (9.3-18.6) | <.001 |
3-y | 1768 | 2.9 (2.2-3.6) | 138 | 14.6 (10.1-19.8) | |
5-y | 1420 | 3.2 (2.5-4) | 111 | 14.6 (10.1-19.8) | |
Diabetes/hyperglycemia | 2026 | 200 | |||
1-y | 1923 | 5.1 (4.2-6.1) | 174 | 13.5 (9.1-18.6) | |
2-y | 1738 | 5.9 (4.9-6.9) | 142 | 14 (9.5-19.2) | .371 |
3-y | 1622 | 6 (5-7.1) | 127 | 14 (9.5-19.2) | |
5-y | 1309 | 6.5 (5.4-7.6) | 105 | 14 (9.5-19.2) | |
Noninfectious liver toxicity | 2112 | 205 | |||
1-y | 1718 | 18.7 (17.1-20.4) | 146 | 29.3 (23.2-35.7) | |
2-y | 1543 | 20.7 (19-22.4) | 118 | 30.7 (24.6-37.2) | .683 |
3-y | 1435 | 21.2 (19.5-23) | 107 | 31.3 (25.1-37.8) | |
5-y | 1102 | 22 (20.3-23.8) | 82 | 31.3 (25.1-37.8) | |
Stroke/seizure | 2116 | 205 | |||
1-y | 2051 | 3.1 (2.4-3.9) | 175 | 15.1 (10.5-20.4) | |
2-y | 1846 | 4.6 (3.7-5.5) | 146 | 17.1 (12.2-22.5) | .081 |
3-y | 1723 | 5.1 (4.2-6.1) | 132 | 18.6 (13.6-24.2) | |
5-y | 1336 | 5.5 (4.6-6.6) | 105 | 18.6 (13.6-24.2) | |
Noninfectious pulmonary dysfunction | 1987 | 175 | |||
1-y | 1845 | 7.2 (6.1-8.4) | 136 | 22.9 (16.9-29.4) | |
2-y | 1656 | 9.9 (8.6-11.2) | 109 | 27.5 (21.1-34.4) | .270 |
3-y | 1550 | 10.4 (9.1-11.7) | 102 | 27.5 (21.1-34.4) | |
5-y | 1252 | 10.7 (9.4-12.1) | 87 | 27.5 (21.1-34.4) |
Organ toxicities reported in CIBMTR (evaluable for the data-intensive research track only). P values are based on significance tests comparing the cumulative incidence between the 2 subpopulations through years 2 to 5. Incidence of late effects within the first year does not have an impact on this P value. One-year estimates are reported as descriptive estimates only.